18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound
|ClinicalTrials.gov Identifier: NCT01713049|
Recruitment Status : Unknown
Verified August 2010 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : October 24, 2012
Last Update Posted : October 24, 2012
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasms||Drug: 18F-FLT||Not Applicable|
- To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard, and to determine whether 18F-FLT PET can increase the specificity in breast lesion diagnosis and thus reduce the unnecessary biopsy.
- To evaluate whether 18F-FLT PET is a cost-effective imaging modality for breast cancer diagnosis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Use of 18F-FLT Positron Emission Tomography to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: A Pilot Study|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2013|
18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
Other Name: FLT
- To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard. [ Time Frame: The biopsy procedures will be scheduled as soon as possible and should be finished within 2 months after 18F-FLT PET. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01713049
|Department of Medical Imaging NTUH||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Jane Wang, MD, PhD +886-2-23123456 ext 65565 firstname.lastname@example.org|
|Principal Investigator:||Jane Wang, PhD||National Taiwan University Hospital|